v3.26.1
Segment Information - Schedule of Segment Revenue and Expenses (Details) - DiamiR Biosciences Corp. [Member] - USD ($)
6 Months Ended 12 Months Ended
Nov. 30, 2025
Nov. 30, 2024
May 31, 2025
May 31, 2024
Segment Reporting Information [Line Items]        
Revenue $ 130,355 $ 442,820 $ 631,729 $ 1,319,531
Research and development        
Research and development     650,591 1,156,860
Other R&D     2,236
General and administrative        
General and administrative     624,388 614,074
Patents     44,363 30,167
Depreciation 9,772 10,155 20,828 20,052
Offering costs     150,526
Rent and facilities     53,483 55,600
Other     35,918 86,204
Interest expense     82,046 48,599
Income taxes (174,546) $ 10,901 17,939 114,403
Net loss $ (409,955)   (743,235) (614,405)
Salaries and benefits [Member]        
Research and development        
Research and development     449,344 692,875
General and administrative        
General and administrative     105,761 117,883
Consultants and contractors [Member]        
Research and development        
Research and development     176,935 278,837
General and administrative        
General and administrative     213,509 292,234
Stock based compensation [Member]        
Research and development        
Research and development     24,312 182,912
General and administrative        
General and administrative     $ 11,934